![Lab Sales & Marketing Compliance: The Current State of EKRA](https://www.g2intelligence.com/wp-content/uploads/2023/02/March23.NLR_.EKRA-1800x1250-1-1080x675.jpg)
Lab Sales & Marketing Compliance: The Current State of EKRA
Sales and marketing operations liability risks and the measures labs should and shouldn’t take to manage those risks.
Sales and marketing operations liability risks and the measures labs should and shouldn’t take to manage those risks.
Last week saw the usual False Claims Act and kickback-related charges, with the biggest action involving urine drug testing.
FDA will still be able to issue EUAs for COVID-19 tests after May 11.
A new method of early, multi-cancer detection could prove more effective for non-invasive screening than other emerging options.
Cost cutting and restructuring has become the order of the day for many lab companies.
While AI as a diagnostic tool is still years away from regular clinical use, recent research is an important step.
Your current COVID-19 testing arrangements may no longer be compliant on May 11.
Most of last week’s healthcare-related actions involved telemedicine in some way, with the lone lab-related case centering on genetic testing.
Roche and Abbott received the most approvals for new lab tests last year.
Economic volatility and uncertainty is also making a significant impact on merger and acquisition activity in the diagnostics space.